AMX0035 showed no benefit over placebo in progressive supranuclear palsy, leading Amylyx to halt its Phase 2b trial. Amylyx shifts focus to avexitide and amyotrophic lateral sclerosis programs, with cash runway through 2026.

Shares in Amylyx Pharmaceuticals ( NASDAQ: AMLX ) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a buy recommendation, accompanied by a price target of $17.

Guggenheim sees $2 billion+ global market potential for PBH treatment by 2035, with $1.8 billion from the U.S. Avexitide's pivotal Phase 3 trial results expected in H1 2026; Phase 2 showed strong clinical results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. UBS analyst Marcus Cole initiated coverage on Amrize Ltd AMRZ with a Neutral rating and ...